Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US
Since Pfizer already owns a tick-borne encephalitis franchise in Europe, the region is a natural first step for the pharma’s upcoming Lyme disease vaccine.
Since Pfizer already owns a tick-borne encephalitis franchise in Europe, the region is a natural first step for the pharma’s upcoming Lyme disease vaccine.
comments(0)
5-min edit window · permanent after that